PASSAGE BIO, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PASSAGE BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $81.00K.
- PASSAGE BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-12-31 was $118.00K.
- PASSAGE BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $44.00K.
- PASSAGE BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-06-30 was $46.00K.
- PASSAGE BIO, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $208.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-03-31 | $81.00K 10-Q · filed 2022-05-16 | $289.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $208.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $44.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $46.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |